



Molecular Targeting Technologies, Inc. Teams Up with B-Bridge, Inc. to Distribute Products in Japan

West Chester, August 23, 2008 - Molecular Targeting Technologies, Inc. (MTTI) announced today that it has engaged B-Bridge Inc. (BBI) as a distributor for Japan. Under this agreement, BBI has the rights to distribute MTTI's NeuroVue[®] and CellVue[®] · SRflour and Steroid Bead product lines for in vitro and in vivo research applications.

Dr. Chris Pak, President and CEO of MTTI commented, "BBI shares our passion in bringing these exciting product lines to the research community in Japan. We envision BBI will play a critical role in capturing the marketplace in Japan"

"We have a large customer base in the areas of metabolic diseases, cancer, cell biology, and drug discovery," stated Hiro Masumoto, President and CEO of B-Bridge International, "and we believe MTTI's novel cell labeling dyes and Steroid Beads offer unique advantages to these investigators."

Dr. Brian Gray, Vice President of Research of MTTI stated, "Our products fit well with those of BBI's and should be extremely valuable for BBIs customers in the areas of cell biology, cancer biology and biochemistry".

Molecular Targeting Technologies, Inc. (MTTI) is a privately held US based Biotechnology Company founded to develop novel medical imaging products for the diagnosis and treatment of cardiovascular disease and cancer. Recently, the company has established an agreement with GeneSeen for the co-development of an innovative approach for targeting breast cancer mRNA with a radiolabeled peptide nucleic acid targeted to the gene of interest and partnered with Bexion Pharmaceuticals which for a first-in-class biologic product for tumor targeting. The company has further expanded its technology to include novel recombinant rabies vaccines for vaccination of wildlife, human anti-rabies monoclonal antibodies for post-exposure prophylaxis, and a fusion protein technology for improved anthrax and botulinum toxin vaccines.

B-Bridge International, Inc. is a privately held US company founded in February 2000 to facilitate and expand access to life sciences technology by connecting investigators with research tools, new technology with business, and entrepreneurs with resources. Headquartered in Mountain View, California, the company also maintains a subsidiary in Tokyo, B-Bridge KK. With access to worldwide markets in the academic, government, pharmaceutical and biotechnology sectors, B-Bridge provides a global bridge for biotechnology transfer, manufacturing, and sales to enhance innovation in the life-sciences.

Contact: Brian Gray, PhD, briangray@mtarget.com, 610.738.7938